About Us

VUZE Medical was incorporated in 2017 in Israel and is financed privately.  Milestones so far include high accuracy and speed on an anatomical model (2018) and in cadaveric surgeries (2019-2020), a first US Patent (2020, with seven more since), first European and Asian patents (2021), FDA 510(k) submission (2021), successful first-in-human surgery (late 2021), FDA 510(k) clearance for minimally-invasive thoracolumbar fixation and augmentation  (2022), the completion of a highly-successful twenty-patient clinical trial (early 2023), cadaveric proofs of concept for pain therapy, sacral  fusions and open surgery (mid 2023) and a second FDA 510(k) clearance including co-operability with a very broad range of 3D and 2D imaging sources from all major vendors (mid 2024).